newsfilter
← Latest News
GlobeNewswire·

Alector Reports Third Quarter 2026 Financial Results and Provides Business Update

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ)